Browse > Article
http://dx.doi.org/10.4014/jmb.1403.03064

A Mixed Formulation of Lactic Acid Bacteria Inhibits Trinitrobenzene-Sulfonic-Acid-Induced Inflammatory Changes of the Colon Tissue in Mice  

Cha, Yeon Suk (School of Biological Sciences, College of Biomedical Sciences and Engineering, Inje University)
Seo, Jae-Gu (Research and Development Center, Cell Biotech Co., Ltd.)
Chung, Myung-Jun (Research and Development Center, Cell Biotech Co., Ltd.)
Cho, Chung Won (School of Biological Sciences, College of Biomedical Sciences and Engineering, Inje University)
Youn, Hyun Joo (School of Biological Sciences, College of Biomedical Sciences and Engineering, Inje University)
Publication Information
Journal of Microbiology and Biotechnology / v.24, no.10, 2014 , pp. 1438-1444 More about this Journal
Abstract
Lactic acid bacteria (LAB) are probiotics that provide numerous beneficial effects on the host body, especially on the intestine. Combining several strains of LAB, we prepared a formulation containing four different LAB and studied its anti-inflammatory activity both in vitro and in vivo. The formulation significantly reduced NO production from RAW 264.7 cells treated with bacterial lipopolysaccharide, indicating that the formulation might include anti-inflammatory activity. The formulation also suppressed inflammatory change induced by trinitrobenzene sulfonic acid (TNBS) in mice, where oral or rectal administration of the formulation protected the colon tissue from the damage by TNBS. Expressions of the IL-6 and FasL genes appeared to be down-regulated by the formulation in TNBS-treated colon tissues, suggesting that the suppression of those genes may be involved in the anti-inflammatory activity of the formulation.
Keywords
Anti-inflammation; probiotics; nitric oxide; IBD; IL-6; FasL;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Triantafillidis J, Merikas E, Georgopoulos F. 2011. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des. Devel. Ther. 5: 185-210.
2 Villa-Morales M, Fernandez-Piqueras J. 2012. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16: 85-101.   DOI
3 Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, et al. 2008. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J. Gastroenterol. 14: 2029-2036.   DOI   ScienceOn
4 Yukawa M, Iizuka M, Horie Y, Yoneyama K, Shirasaka T, Itou H, et al. 2002. Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. Int. J. Colorectal Dis. 17: 70-76.   DOI
5 Wang K, Yuan CP, Wang W, Yang ZQ, Cui W, Mu LZ, et al. 2010. Expression of interleukin 6 in brain and colon of rats with TNBS-induced colitis. World J. Gastroenterol. 16: 2252- 2259.   DOI
6 Xavier R, Podolsky D. 2007. Unraveling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.   DOI   ScienceOn
7 Yamamoto J, Maeno K, Takada T, Kakutani K, Yurube T, Zhang Z, et al. 2013. Fas ligand plays an important role for the production of pro-inflammatory cytokines in intervertebral disc nucleus pulposus cells. J. Orthop. Res. 31: 608-615.   DOI
8 Fuller R. 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66: 365-378.   DOI
9 Nakano K, Saito K, Mine S, Matsushita S, Tanaka Y. 2007. FasL expressed on activated T cell, interact with Fas homeostasis. Apoptosis 12: 45-54.   DOI
10 Mudter J, Amoussina L, Schenk M, Yu J, Brustle A, Weigmann B, et al. 2008. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118: 2415-2426.
11 Prideaux L, Kamm MA, de Cruz PP, Chan FKL, Ng SC. 2012. Inflammatory bowel disease in Asia: a systematic review. J. Gastroenterol. Hepatol. 27: 1266-1280.   DOI   ScienceOn
12 LeBlanc JG, de Moreno de Leblanc A, Perdigon G, Miyoshi A, Rochat T, Bermudez-Humaran L, et al. 2008. Antiinflammatory properties of lactic acid bacteria: current knowledge, applications and prospects. Antiinfect. Agents Med. Chem. 7: 148-154.   DOI
13 Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR, et al. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126: 131-138.   DOI   ScienceOn
14 Hong T, Jin G, Yoshino G, Miura M, Maeda Y, Cho S, Cyong J. 2002. Protective effects of Polygalae root in experimental TNBS-induced colitis in mice. J. Ethnopharmacol. 79: 341-346.   DOI
15 Larsson A, Melgar S, Rehnström E, Michaelsson E, Svensson L, Hockings P, et al. 2006. MRI of colon wall thickness - a biomarker in experimental mouse inflammatory disease? Inflamm. Bowel Dis. 12: 478-485.   DOI
16 Leon F, Smythies LE, Smith PD, Kelsall BL. 2006. Involvement of dendritic cells in the pathogenesis of inflammatory bowel disease. Adv. Exp. Med. Biol. 579: 117-132.   DOI
17 Lettau M, Paulsen M, Schmidt H, Janssen O. 2011. Insights into the molecular regulation of FasL (CD178) biology. Eur. J. Cell Biol. 90: 456-466.   DOI
18 Lin WW, Hsieh SL. 2011. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem. Pharmacol. 81: 838-847.   DOI
19 Masood MI, Qadir MI, Shirazi JH, Khan IU. 2011. Beneficial effects of lactic acid bacteria on human beings. Crit. Rev. Microbiol. 37: 91-98.   DOI   ScienceOn
20 Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, et al. 2013. The role of intestinal microbiota and the immune system. Eur. Rev. Med. Pharmacol. Sci. 17: 323-333.
21 Seo JG, Chung MJ, Lee HG. 2011. Alleviation of atopic dermatitis through probiotic and mixed-probiotic treatments in an atopic dermatitis model. Korean J. Food Sci. Anim. Resour. 31: 420-427.   과학기술학회마을   DOI   ScienceOn
22 Sacco R, Waters W, Rudolph K, Drew M. 2006. Comparative nitric oxide production by LPS-stimulated monocytederived macrophages from Ovis canadensis and Ovis aries. Comp. Immunol. Microbiol. Infect. Dis. 29: 1-11.   DOI   ScienceOn
23 Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. 1999. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 117: 1089-1097.   DOI
24 Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. 2003. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52: 237-242.   DOI   ScienceOn
25 Souza HS, Tortori CJ, Castelo-Branco MT, Carvalho AT, Margallo VS, Delgado CF, et al. 2005. Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways. Int. J. Colorectal Dis. 20: 277-286.   DOI
26 Weigelin B, Krause M, Friedl P. 2011. Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunol. Lett. 138: 19-21.   DOI
27 Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M. 2013. Probiotics: properties, examples, and specific applications. Cold Spring Harb. Perspect. Med. 3: 1-15.
28 Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588.   DOI   ScienceOn
29 Baumgart DC, Carding SR. 2007. Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640.   DOI   ScienceOn
30 Baumgart DC, Sandborn WJ. 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.   DOI   ScienceOn
31 Conte MP, Schippa S. Zamboni I, Penta M, Chiarini F, Seganti L, et al. 2006. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 55: 1760-1767.   DOI   ScienceOn
32 Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. 2008. Immunomodulatory effects of probiotics in the intestinal tract. Curr. Issues Mol. Biol. 10: 37-54.